AlphaVax Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

AlphaVax General Information

Description

Developer of vaccines for cancer immunotherapy intended for anti-infective and anti-cancer vaccines. The company engages proprietary RNA replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) to treat diseases such as influenza, cytomegalovirus, HIV, prostate, and breast cancer among others, enabling healthcare providers to have access to novel therapies to better treat diseases in patients.

Contact Information

Website
www.alphavax.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Triangle Drive
  • Po Box 110307, Research Triangle Park
  • Durham, NC 27709-0307
  • United States
+1 (800)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2 Triangle Drive
  • Po Box 110307, Research Triangle Park
  • Durham, NC 27709-0307
  • United States
+1 (800)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlphaVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Apr-2023 Completed Generating Revenue
8. Grant 10-Jul-2007 Completed Generating Revenue
7. Later Stage VC (Series E) 05-Feb-2007 Completed Generating Revenue
6. Grant 19-Oct-2005 Completed Generating Revenue
5. Grant 17-Nov-2004 Completed Generating Revenue
4. Later Stage VC 06-Jan-2004 Completed Generating Revenue
3. Grant 21-Oct-2003 Completed Generating Revenue
2. Later Stage VC (Series C) 03-Apr-2002 $11M $19.2M Completed Generating Revenue
1. Early Stage VC (Series B) 28-Feb-2001 $8.2M $8.2M Completed Generating Revenue
To view AlphaVax’s complete valuation and funding history, request access »

AlphaVax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of vaccines for cancer immunotherapy intended for anti-infective and anti-cancer vaccines. The company engages
Biotechnology
Durham, NC
9 As of 2022

Ballerup, Denmark
 

Gaithersburg, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AlphaVax Competitors (63)

One of AlphaVax’s 63 competitors is Symphogen, a Formerly VC-backed company based in Ballerup, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Symphogen Formerly VC-backed Ballerup, Denmark
NexImmune Formerly VC-backed Gaithersburg, MD
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Gracell Formerly VC-backed Shanghai, China
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 63 competitors. Get the full list »

AlphaVax Patents

  • 162

    Total Documents Applications and Grants

  • Total Patents Families

  • 106

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

AlphaVax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2015249175-A1 Alphavirus replicon particles expressing trp2 Inactive 08-Apr-2009
US-20120128714-A1 Alphavirus replicon particles expressing trp2 Inactive 08-Apr-2009
ES-2540958-T3 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
US-20200113984-A1 Alphavirus replicon particles expressing trp2 Pending 08-Apr-2009
AU-2017276161-A1 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
To view AlphaVax’s complete patent history, request access »

AlphaVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AlphaVax Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute Of Allergy and Infectious Diseases Government
National Institute for Allergy and Infectious Disease Government
To view AlphaVax’s complete investors history, request access »

Ready to get started?

Request a free trial

AlphaVax FAQs

  • When was AlphaVax founded?

    AlphaVax was founded in 1997.

  • Where is AlphaVax headquartered?

    AlphaVax is headquartered in Durham, NC.

  • What is the size of AlphaVax?

    AlphaVax has 9 total employees.

  • What industry is AlphaVax in?

    AlphaVax’s primary industry is Biotechnology.

  • Is AlphaVax a private or public company?

    AlphaVax is a Private company.

  • What is AlphaVax’s current revenue?

    The current revenue for AlphaVax is .

  • How much funding has AlphaVax raised over time?

    AlphaVax has raised $32.8M.

  • Who are AlphaVax’s investors?

    National Institute Of Allergy and Infectious Diseases and National Institute for Allergy and Infectious Disease have invested in AlphaVax.

  • Who are AlphaVax’s competitors?

    Symphogen, NexImmune, Aro Biotherapeutics, Gracell, and Kite Pharma are some of the 63 competitors of AlphaVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »